Ocular Therapeutix, Inc.

NASDAQ:OCUL

Biotechnology

Healthcare
$5.94 -1.17%

-$0.11 today

Market cap
$1.31B
Beta
0.90
P/E (TTM)
-7.3
EPS (TTM)
-$1.30
52W Low $6.23High $16.44

Volume 3.67M

Average 3.00M

OCUL Interest Income

Income earned on cash, deposits, and investments held by the company.

Ocular Therapeutix, Inc.NASDAQ: OCUL

Interest Income · Q1 FY2026 · quarter ended Mar 2026

Interest income growth accelerates

Q1 FY2026 interest income of $6.05M rose 58.1% year over year, ahead of the +1.9% change in trailing-twelve-month interest income. Sequentially, it fell 17.6% from the prior quarter. Over 3 fiscal years it compounded at +184.4% a year.

Context

  • Interest income amounted to 35.4% of revenue in FY2025, up 3.6 pp from a year earlier.
  • Interest income increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +58.1% holds above the trailing-twelve-month pace of +1.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$6.05M-17.6% QoQ
Last fiscal yearDec 2025
$18.36M-9.5% YoY
LTMMar 2026
$20.58M+1.9% YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+58.1%——
1 year-9.5%——
3-year CAGR+184.4%——
5-year CAGR——
10-year CAGR——

Interest Income history

USD · from the income statement

Latest · FY2025
18.36M USD
Year-over-year change
-9.5%
4-year CAGR
+385.6%

Interest Income vs competitors

How OCUL compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +1.9% is the highest of 9, against a peer median of -19.1%.
  • Interest income amounts to 39.5% of revenue for OCUL, versus a peer median of 1.5%.
OCUL Competitors
Interest Income for OCUL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OCULOcular Therapeutix, Inc.LTM Mar 2026$20.58M USD+1.9%+184.4%39.5%
BLCOBausch + Lomb CorporationLTM Jun 2026$14M USD-6.7%+26.0%0.3%
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026$10.45M USD-28.9%+76.7%137.3%
GKOSGlaukos CorporationLTM Jun 2026$9.77M USD-9.9%+65.2%1.6%
KODKodiak Sciences Inc.LTM Sep 2026$4.55M USD-22.7%-13.9%—
STAASTAAR Surgical CompanyLTM Apr 2026$4.14M USD-28.1%+23.3%1.4%
SGPSpyGlass Pharma, Inc. Common StockFY2025$3.11M USD———
OCSOculis Holding AGLTM Mar 2026CHF 1.76M CHF-15.4%+137.6%349.0%
OCGNOcugen, Inc.LTM Mar 2026$483K USD-3.4%-13.0%10.8%
OTLKOutlook Therapeutics, Inc.LTM Mar 2026$3 USD-100.0%—0.0%
HROWHarrow Health, Inc.LTM Mar 2026$0 USD——0.0%
Peer median (excluding OCUL) —-19.1%+26.0%1.5%

Competitors are the stored peer set for OCUL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue43.52M51.49M58.44M63.72M51.82M
Cost of Revenue4.41M4.54M5.28M5.63M6.57M
Gross Profit39.12M46.95M53.16M58.1M45.25M
Gross Margin89.9%91.2%91.0%91.2%87.3%
Research & Development50.08M53.46M61.06M127.64M197.1M
Selling, General & Admin67.07M72.15M74.49M102.24M118.3M
Operating Expenses117.15M125.61M135.54M229.88M315.39M
Depreciation & Amortization2.42M2.11M2.98M3.79M4.32M
EBITDA2.54M(61.91M)(66.42M)(176.14M)(249.78M)
EBITDA Margin5.8%-120.2%-113.6%-276.4%-482.0%
Operating Income(78.04M)(78.65M)(82.38M)(171.78M)(270.02M)
Operating Margin-179.3%-152.7%-141.0%-269.6%-521.0%
Interest Income33K798K3.98M20.28M18.36M
Interest Expense6.67M7.02M11.34M13.58M11.84M
Other Income / Expenses71.48M7.62M1.65M(21.73M)4.08M
Income Before Tax(6.55M)(71.04M)(80.74M)(193.51M)(265.94M)
Pre-Tax Margin-15.1%-138.0%-138.1%-303.7%-513.2%
Income Tax Expense00000
Net Income(6.55M)(71.04M)(80.74M)(193.51M)(265.94M)
Net Margin-15.1%-138.0%-138.1%-303.7%-513.2%
EPS (Basic)(1.05)(1.04)(1.09)(1.22)(1.42)
EPS (Diluted)(0.98)(0.97)(1.02)(1.22)(1.42)
Weighted Avg Shares76.39M76.88M79.83M158.27M187.24M
Weighted Avg Shares (Diluted)82.16M82.64M85.6M158.27M187.24M

Ocular Therapeutix, Inc.

NASDAQ:OCUL

Intrinsic Alpha fair value

Locked

Current Price

$5.94

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.